Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-st-segment elevation acute coronary syndrome

Thrombosis Research

Volumn 124, Issue 6, 2009, Pages 678-682

  Perez de Prado, Armando ^a   Cuellas, Carlos ^a   Diego, Alejandro ^a   de Miguel, Antonio ^a   Samaniego, Beatriz ^a   Alonso Orcajo, Norberto ^a   Carbonell, Raul ^a   Pascual, Cristina ^a   Fernandez Vazquez, Felipe ^a   Calabozo, Ramon G ^a  

^a HOSPITAL DE LEÓN   (Spain)

Author keywords

Acute Coronary Syndrome; Myonecrosis; Percutaneous Coronary Intervention; Platelet Reactivity

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; ENOXAPARIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; PURINERGIC P2Y12 RECEPTOR; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; ARTERY EMBOLISM; ARTERY OCCLUSION; ARTERY SPASM; ARTICLE; BIOCHEMICAL EQUIPMENT; BLEEDING; BLOOD EXAMINATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FATALITY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; INHIBITION KINETICS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE NECROSIS; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEPTOR BLOCKING; RECURRENT DISEASE; REVASCULARIZATION; ST SEGMENT ELEVATION; STROKE; SURGICAL PATIENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BLOOD PLATELETS; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PLATELET AGGREGATION; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 70449517485     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.04.004     Document Type: Article

References (48)

1. Trip M.D., Cats V.M., van Capelle F.J., and Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322 (1990) 1549-1554
2. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 345 (2001) 494-502
3. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The pci-cure study. Lancet 358 (2001) 527-533
4. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. Jama 288 (2002) 2411-2420
5. Howard P.A. Aspirin resistance. Ann Pharmacother 36 (2002) 1620-1624
6. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
7. Gurbel P.A., and Bliden K.P. Interpretation of platelet inhibition by clopidogrel and the effect of non-responders. J Thromb Haemost 1 (2003) 1318-1319
8. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
9. Gurbel P.A., Cummings C.C., Bell C.R., Alford A.B., Meister A.F., and Serebruany V.L. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The plavix reduction of new thrombus occurrence (pronto) trial. Am Heart J 145 (2003) 239-247
10. Muller I., Besta F., Schulz C., Massberg S., Schonig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
11. Lepantalo A., Virtanen K.S., Heikkila J., Wartiovaara U., and Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 25 (2004) 476-483
12. Wiviott S.D., and Antman E.M. Clopidogrel resistance: A new chapter in a fast-moving story. Circulation 109 (2004) 3064-3067
13. Lev E.I., Patel R.T., Maresh K.J., Guthikonda S., Granada J., DeLao T., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
14. Wang T.H., Bhatt D.L., and Topol E.J. Aspirin and clopidogrel resistance: An emerging clinical entity. Eur Heart J 27 (2006) 647-654
15. von Beckerath N., Kastrati A., Wieczorek A., Pogatsa-Murray G., Sibbing D., Graf I., et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28 (2007) 1814-1819
16. Cuisset T., Frere C., Quilici J., Morange P.E., Nait-Saidi L., Mielot C., et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-st elevation acute coronary syndromes. Thromb Haemost 97 (2007) 282-287
17. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., and Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate?. J Am Coll Cardiol 49 (2007) 657-666
18. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
19. Wheeler G.L., Braden G.A., Steinhubl S.R., Kereiakes D.J., Kottke-Marchant K., Michelson A.D., et al. The ultegra rapid platelet-function assay: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 143 (2002) 602-611
20. Quinn M.J., Murphy R.T., Dooley M., Foley J.B., and Fitzgerald D.J. Occupancy of the internal and external pools of glycoprotein iib/iiia following abciximab bolus and infusion. J Pharmacol Exp Ther 297 (2001) 496-500
21. van Werkum J.W., van der Stelt C.A., Seesing T.H., Hackeng C.M., and ten Berg J.M. A head-to-head comparison between the verifynow p2y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 4 (2006) 2516-2518
22. von Beckerath N., Pogatsa-Murray G., Wieczorek A., Sibbing D., Schomig A., and Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 95 (2006) 910-911
23. Lordkipanidze M., Pharand C., Nguyen T.A., Schampaert E., Palisaitis D.A., and Diodati J.G. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 29 (2008) 2877-2885
24. Kim K.E., Woo K.S., Goh R.Y., Quan M.L., Cha K.S., Kim M.H., et al. Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients. Int J Lab Hematol (2008)
25. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
26. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., and Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention: Results of the armyda-pro (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol 52 (2008) 1128-1133
27. Marcucci R., Gori A.M., Paniccia R., Giusti B., Valente S., Giglioli C., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to adp detected by a point-of-care assay: A 12-month follow-up. Circulation 119 (2009) 237-242
28. Steinhubl S.R., Talley J.D., Braden G.A., Tcheng J.E., Casterella P.J., Moliterno D.J., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the gold (au-assessing ultegra) multicenter study. Circulation 103 (2001) 2572-2578
29. Campo G., Valgimigli M., Gemmati D., Percoco G., Tognazzo S., Cicchitelli G., et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: Insights into the strategy study. J Am Coll Cardiol 48 (2006) 2178-2185
30. Cuisset T., Frere C., Quilici J., Morange P.E., Nait-Saidi L., Carvajal J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-st-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
31. Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al. Platelet reactivity in patients and recurrent events post-stenting: Results of the prepare post-stenting study. J Am Coll Cardiol 46 (2005) 1820-1826
32. Hochholzer W., Trenk D., Bestehorn H.P., Fischer B., Valina C.M., Ferenc M., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
33. Samara W.M., Bliden K.P., Tantry U.S., and Gurbel P.A. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 115 (2005) 89-94
34. Prasad A., Singh M., Lerman A., Lennon R.J., Holmes Jr. D.R., and Rihal C.S. Isolated elevation in troponin t after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 48 (2006) 1765-1770
35. Ramirez-Moreno A., Cardenal R., Pera C., Pagola C., Guzman M., Vazquez E., et al. Predictors and prognostic value of myocardial injury following stent implantation. Int J Cardiol 97 (2004) 193-198
36. Miller W.L., Garratt K.N., Burritt M.F., Lennon R.J., Reeder G.S., and Jaffe A.S. Baseline troponin level: Key to understanding the importance of post-pci troponin elevations. Eur Heart J 27 (2006) 1061-1069
37. Kini A.S., Lee P., Marmur J.D., Agarwal A., Duffy M.E., Kim M.C., et al. Correlation of postpercutaneous coronary intervention creatine kinase-mb and troponin i elevation in predicting mid-term mortality. Am J Cardiol 93 (2004) 18-23
38. Thygesen K., Alpert J.S., and White H.D. Universal definition of myocardial infarction. Eur Heart J 28 (2007) 2525-2538
39. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
40. Chen W.H., Lee P.Y., Ng W., Tse H.F., and Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
41. Geisler T., Langer H., Wydymus M., Gohring K., Zurn C., Bigalke B., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27 (2006) 2420-2425
42. Montalescot G., Sideris G., Meuleman C., Bal-dit-Sollier C., Lellouche N., Steg P.G., et al. A randomized comparison of high clopidogrel loading doses in patients with non-st-segment elevation acute coronary syndromes: The albion (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial. J Am Coll Cardiol 48 (2006) 931-938
43. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the armyda-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) study. Circulation 111 (2005) 2099-2106
44. Acc/aha/scai practice guidelines, february 21, 2006. Circulation 113 (2006) e166-286
45. Moliterno D.J., and Steinhubl S.R. Clopidogrel for percutaneous coronary revascularization: Time for more pretreatment, retreatment, or both?. JAMA 294 (2005) 1271-1273
46. Kastrati A., von Beckerath N., Joost A., Pogatsa-Murray G., Gorchakova O., and Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110 (2004) 1916-1919
47. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 51 (2008) 1404-1411
48. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015